With COVID-19 testing revenues at risk, DiaSorin has taken the inorganic route to plug the potential revenue gap. The Luminex acquisition strengthens DiaSorin’s positioning in the molecular diagnostics space, broadens its presence in the US, and creates additional value through life science offerings. Importantly, the deal is attractive in valuation terms and should be earnings accretive from FY22 onwards. However, fierce competition in the multiplexing space could be a key headwind as managemen ....
27 Apr 2021
DiaSorin gets its hands on Luminex
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
DiaSorin gets its hands on Luminex
- Published:
27 Apr 2021 -
Author:
Sumit Sayal -
Pages:
3
With COVID-19 testing revenues at risk, DiaSorin has taken the inorganic route to plug the potential revenue gap. The Luminex acquisition strengthens DiaSorin’s positioning in the molecular diagnostics space, broadens its presence in the US, and creates additional value through life science offerings. Importantly, the deal is attractive in valuation terms and should be earnings accretive from FY22 onwards. However, fierce competition in the multiplexing space could be a key headwind as managemen ....